A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome
Kisely, Steve, Sawyer, Emily, Robinson, Gail, and Siskind, Dan (2015) A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome. Schizophrenia Research, 166. pp. 178-186.
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
Background: Depot antipsychotics are commonly used to improve adherence and clinical outcomes such as relapse and readmission. Dosing regimens vary but are commonly two- and four-weekly. To date, the effect of administration at two-weekly or four-weekly intervals on outcome has not been examined in a meta-analysis.
Aims: A systematic review and meta-analysis on whether the frequency of depot antipsychotic administration (e.g., two- vs four-weekly) makes any difference to compliance and outcome.
Methods: A systematic search of Medline, EMBASE and PsycInfo for RCTs that compared the frequency of depot administration (e.g., two- vs four-weekly) for an equivalent dose. Outcomes were compliance, psychiatric symptomatology, quality of life, adverse drug reactions (ADRs), patient preference, admission rates, bed-days and costs.
Results: Seven studies from eight papers (n = 3994) were found covering olanzapine, paliperidone, risperidone, haloperidol and fluphenazine enanthate/decanoate with follow-up of up to one year. Meta-analyses were possible for psychotic symptoms and ADRs. There were no differences in psychotic symptoms or quality of life between two- and four-weekly doses. Health service use was not reported. For ADRs, the only significant difference detected was that two-weekly injections were less likely to lead to site pain (RR 0.16, 95% CI 0.07–0.38; 2 studies n = 1667). There were no differences in other ADRs.
Conclusions: There were surprisingly little data on the effect of dosing frequency for an equivalent dose on clinical outcomes. There is a need for long-term studies of a wide range of outcomes including cost-effectiveness. Claims for advantages of new preparations over others require careful evaluation.
Item ID: | 44335 |
---|---|
Item Type: | Article (Research - C1) |
ISSN: | 1573-2509 |
Keywords: | depot antipsychotic; LAI; dosing frequency; outcomes |
Funders: | University of Queensland |
Date Deposited: | 16 Jun 2016 23:20 |
FoR Codes: | 11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111714 Mental Health @ 50% 11 MEDICAL AND HEALTH SCIENCES > 1115 Pharmacology and Pharmaceutical Sciences > 111502 Clinical Pharmacology and Therapeutics @ 50% |
SEO Codes: | 92 HEALTH > 9202 Health and Support Services > 920209 Mental Health Services @ 100% |
Downloads: |
Total: 2 |
More Statistics |